CpG-oligodeoxynucleotide-induced TLR9 activation regulates macrophage TREM-1 expression and shedding

Innate Immunity

Volumn 19, Issue 6, 2013, Pages 623-630

  Molad, Yair ^a,b   Pokroy Shapira, Elisheva ^b   Carmon, Vered ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

Author keywords

CpG oligodeoxynucleotide; macrophage; metalloproteinase (MMP) 9; Toll like receptor; Triggering receptor expressed on myeloid cells (TREM) 1

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GELATINASE B; TOLL LIKE RECEPTOR 9; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 1;

ANIMAL CELL; ARTICLE; CELL SURFACE; CONTROLLED STUDY; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; UPREGULATION; ZYMOGRAPHY;

CPG-OLIGODEOXYNUCLEOTIDE; MACROPHAGE; METALLOPROTEINASE (MMP)-9; TOLL-LIKE RECEPTOR; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS (TREM)-1;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL LINE; CHLOROQUINE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HUMANS; LIPOPOLYSACCHARIDES; MACROPHAGE ACTIVATION; MACROPHAGES, PERITONEAL; MATRIX METALLOPROTEINASE 9; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; OLIGODEOXYRIBONUCLEOTIDES; RECEPTORS, IMMUNOLOGIC; SEPSIS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 9;

EID: 84887856706     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425913476970     Document Type: Article

References (33)

1. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006 ; 124: 783-801
2. Trivedi S, Greidinger EL. Endosomal Toll-like receptors in autoimmunity: mechanisms for clinical diversity. Therapy. 2009 ; 6: 433-442
3. Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev. 2009 ; 61: 195-204
4. Rhee JW, Lee KW, Sohn WJ, Lee Y, Jeon OH, Kwon HJ, Kim DS. Regulation of matrix metalloproteinase-9 gene expression and cell migration by NF-kappa B in response to CpG-oligodeoxynucleotides in RAW 264.7 cells. Mol Immunol. 2007 ; 44: 1393-1400
5. Horton CG, Pan ZJ, Farris AD. Targeting Toll-like receptors for treatment of SLE. Mediators Inflamm. 2010 ; 2010: pii: 498980 - pii: 498980
6. Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol. 2000 ; 164: 4991-4995
7. Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and signal integration. Nat Immunol. 2006 ; 7: 1266-1273
8. Chen LC, Laskin JD, Gordon MK, Laskin DL. Regulation of TREM expression in hepatic macrophages and endothelial cells during acute endotoxemia. Exp Mol Pathol. 2008 ; 4: 145-155
9. Sharif O, Knapp S. From expression to signaling: roles of TREM-1 and TREM-2 in innate immunity and bacterial infection. Immunobiology. 2008 ; 213: 701-713
10. Ford JW, McVicar DW. TREM and TREM-like receptors in inflammation and disease. Curr Opin Immunol. 2009 ; 21: 38-46
11. Kuai J, Gregory B, Hill A, Pittman DD, Feldman JL, Brown T, et al. TREM-1 expression is increased in the synovium of rheumatoid arthritis patients and induces the expression of pro-inflammatory cytokines. Rheumatology (Oxford). 2009 ; 48: 1352-1358
12. Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature. 2001 ; 410: 1103-1107
13. Gibot S, Buonsanti C, Massin F, Romano M, Kolopp-Sarda MN, Benigni F, et al. Modulation of the triggering receptor expressed on the myeloid cell type 1 pathway in murine septic shock. Infect Immun. 2006 ; 74: 2823-2830
14. Schenk M, Bouchon A, Seibold F, Mueller C. TREM-1-expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J Clin Invest. 2007 ; 117: 3097-3106
15. Gómez-Piña V, Soares-Schanoski A, Rodríguez-Rojas A, Del Fresno C, García F, Vallejo-Cremades MT, et al. Metalloproteinases shed TREM-1 ectodomain from lipopolysaccharide-stimulated human monocytes. J Immunol. 2007 ; 179: 4065-4073
16. Knapp S, Gibot S, de Vos A, Versteeg HH, Colonna M, van der Poll T. Cutting edge: expression patterns of surface and soluble triggering receptor expressed on myeloid cells-1 in human endotoxemia. J Immunol. 2004 ; 173: 7131-7134
17. Lim EJ, Lee SH, Lee JG, Kim JR, Yun SS, Baek SH, Lee C. Toll-like receptor 9 dependent activation of MAPK and NF-kB is required for the CpG ODN-induced matrix metalloproteinase-9 expression. Exp Mol Med. 2007 ; 39: 239-245
18. Rhee JW, Lee KW, Sohn WJ, Lee Y, Jeon OH, Kwon HJ, Kim DS. Regulation of matrix metalloproteinase-9 gene expression and cell migration by NF-kappa B in response to CpG-oligodeoxynucleotides in RAW 264.7 cells. Mol Immunol. 2007 ; 44: 1393-1400
19. Arts RJW, Joosten LAB, van der Meer JWM and Netea MG. TREM-1: intracellular signaling pathways and intraction with pattern recognition receptors. J Leuk Biol. Epub ahead of print 29 Oct 2012.
20. Klesney-Tait J, Keck K, Li X, Gilfillan S, Otero K, Baruah S, et al. Transepithelial migration of neutrophils into the lung requires TREM-1. J Clin Invest. Epub ahead of print 17 December 2012.
21. Elkins KL, Rhinehart-Jones TR, Stibitz S, Conover JS, Klinman DM. Bacterial DNA containing CpG motifs stimulates lymphocyte-dependent protection of mice against lethal infection with intracellular bacteria. J Immunol. 1999 ; 162: 2291-2298
22. Krieg AM, Love-Homan L, Yi AK, Harty JT. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol. 1998 ; 161: 2428-2434
23. Verthelyi D, Gursel M, Kenney RT, Lifson JD, Liu S, Mican J, Klinman DM. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection. J Immunol. 2003 ; 170: 4717-4723
24. Waag DM, McCluskie MJ, Zhang N, Krieg AM. A CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei. Infect Immun. 2006 ; 74 (3). 1944-1948
25. Wongratanacheewin S, Kespichayawattana W, Intachote P, Pichyangkul S, Sermswan RW, Krieg AM, Sirisinha S. Immunostimulatory CpG oligodeoxynucleotide confers protection in a murine model of infection with Burkholderia pseudomallei. Infect Immun. 2004 ; 72: 4494-4502
26. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol. 2002 ; 20: 709-760
27. Krieg AM, Davis HL. Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther. 2001 ; 3: 15-24
28. Roquilly A, Gautreau L, Segain JP, de Coppet P, Sebille V, Jacqueline C, et al. CpG-ODN and MPLA prevent mortality in a murine model of post-hemorrhage-Staphyloccocus aureus pneumonia. PLoS One. 2010 ; 5: e13228 - e13228
29. Weighardt H, Feterowski C, Veit M, Rump M, Wagner H, Holzmann B. Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. J Immunol. 2000 ; 165: 4537-4545
30. Murakami Y, Akahoshi T, Aoki N, Toyomoto M, Miyasaka N, Kohsaka H. Intervention of an inflammation amplifier, triggering receptor expressed on myeloid cells 1, for treatment of autoimmune arthritis. Arthritis Rheum. 2009 ; 60: 1615-1623
31. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol. 2002 ; 37: 375-536
32. Bond M, Fabunmi RP, Baker AH, Newby AC. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS let. 1998 ; 435: 29-34
33. Opdenakker G, Van den Steen PE, Van Damme J. Gelatinase B: a tuner and amplifier of immune functions. Trends Immunol. 2001 ; 22: 571-579